Gynecomastia Extension Study

• Status: Completed
• Trial end date: 2002-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to look at the effect of anastrozole (ZD1033, Arimidex™) in reducing gynecomastia in pubertal boys treated with placebo in Trial 1033US/0006 (another anastrozole study).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Anastrozole

Criteria

Inclusion Criteria:

• Subjects must have entered Trial 1033US/0006 and completed 6 months of treatment and one month of follow-up.

• Subjects must have gynecomastia, with one breast measuring at least 3 cm in diameter.

Exclusion Criteria:

• Subjects who have been given medications known to cause gynecomastia within the previous 3 months